Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Art Vandelay AIA who wrote (2815)	5/18/1999 9:30:00 AM
From: wolfdog2	Respond to of 10280

I closed out the short portion of my hedges yesterday. I thought, despite the terrible looking charts, that SEPR held up very well. Also I was impressed with the way the folks at SEPR handled the "bad" news Friday as well as the cc yesterday. The premarket bid and ask are encouraging this morning. Last I looked, the bid was over 80.

To: Art Vandelay AIA who wrote (2815)	5/18/1999 9:55:00 AM
From: Don Miller	Respond to of 10280

<For those of us who are long term and care to analytically judge at what's really happened, this is a SCA-REEEEEAMING buy opportunity. For those of us that need the stock to be at $XXX in X months, or weeks, or days (like me with those extra 90 May calls), this just doesn't look like the place to be. For those that want to look at the merits of the business model, we're here and waiting. For those who need news every month to keep themselves motivated, they probably should look elsewhere.> Ahmen, This is but one good example of why this board is so valuable. I am proud to be associated with you all.

To: Art Vandelay AIA who wrote (2815)	5/18/1999 11:23:00 AM
From: M. Ramle	Read Replies (1) \| Respond to of 10280

Art: If based on the latest "Institutional Holding" figures which seem to remain unchanged from the previous quarter, who on earth do you think has been behind the recent sharp decline in SEPR's value ($141 to $78) ??? Keeping in mind that the float appears to be roughly around 38M shares. Thanks for your input and Good Luck. Mazen

To: Art Vandelay AIA who wrote (2815)	5/18/1999 1:25:00 PM
From: Andy Goett	Read Replies (2) \| Respond to of 10280

Last night on one of the network news broadcasts (I forget which), there was a piece on a new treatment for allergies. It involves taking injections once a month to block allergic reactions. While it is still under development, the reporter said that the drug is very effective, quick acting, and that there are no apparent side effects. The reporter said that the developers expect the drug to be available within three years. I know that there has been some discussion of this drug or a similar one on this thread in the past. I recall that its potential was downplayed because it requires taking injections and for other technical reasons that I don't understand. However, the news piece last night sounded much more positive. My question is how much of a threat is there that this drug (or some other anti-allergy research, for that matter) will make several of the "improved" antihistimine drugs that Sepracor is working on obsolete?